This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.

Retrospective analysis of banked tissue from Breast Cancer patients.

  • Research type

    Research Study

  • Full title

    Early prediction and targeting of Neo-Adjuvant Chemo-Therapy persistent cells in triple negative breast cancer

  • IRAS ID

    312311

  • Contact name

    Robert B Clarke

  • Contact email

    robert.clarke@manchester.ac.uk

  • Sponsor organisation

    University of Manchester

  • Duration of Study in the UK

    3 years, 0 months, 1 days

  • Research summary

    Triple Negative Breast Cancers (TNBC) are not sensitive to standard therapies against oestrogen/progesterone receptor (ER/PR) or human epidermal growth factor receptor 2 (HER2). TNBCs are characterized by their fast growing and potential to invade other tissues in the body leading to a poor prognosis. Therefore, identifying specific mechanisms in the way the cells grow will lead to better targeted drug therapies and new drug combinations in an area where there is an urgent clinical need.
    Currently, newly diagnosed triple negative breast cancer (TNBC) patients are treated with chemotherapy before surgery to reduce the tumour size and assess if the tumour is sensitive to the treatment. This response is then used to determine an overall prognosis.
    Those patients whose tumours disappear are said to have an excellent long-term survival while those with some tumour remaining have 50% more chance of lethal spread to other tissue that can rapidly progress.
    Therefore, the challenge is to identify tumours with changes that allow the tumour to partly survive and the signalling pathways that regulate these changes. Once these can be recognised earlier in the course of treatment a more effective therapy can be given and unnecessary treatment and toxicity avoided.

  • REC name

    North of Scotland Research Ethics Committee 1

  • REC reference

    22/NS/0118

  • Date of REC Opinion

    11 Aug 2022

  • REC opinion

    Favourable Opinion

We need your feedback!

We are still testing the new HRA website to ensure it meets your needs. Please complete our short feedback form.